MedTrace Logo

The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)

NCT02438111 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2023-04-18

No results posted yet for this study

Summary

The primary objective of this study is to assess whether compositional and functional alterations of the gut metagenome may be related to AMD. The primary variable for this assessment is the composition of the gut metagenome which will be analyzed by shotgun sequencing to characterize the faecal metagenome. The secondary endpoint is to assess whether single nucleotide polymorphisms in CFH, ARMS2, C3, PLEKHA1, HTRA-1, VEGF-A, VEGF-B, VEGFR and APOE genes which have been shown to be risk factors for the development of AMD and other macular diseases correlate with alterations in the gut metagenome .

Conditions

  • Age Related Macular Degeneration

Interventions

GENETIC

metagenome

metagenome

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Martin Zinkernagel, M.D, PhD · Department of Ophthalmology, University Hospital Bern, Switzerland

  • Martin S Zinkernagel, MD, PhD · Department of Ophthalmology, University Hospital Bern, Switzerland

  • Martin Fiedler, MD · University Hospital Bern, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02438111 on ClinicalTrials.gov